Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma

Table 1 comparison between human and canine DLBCL

Species	Median age of occurrence	Molecular biomarkers	Current treatment	PFS/OS
Human	≥ 65 years [19]	Myc, BCL2, BCL6 [20]	R-CHOP [17]	> 8 years [19]
Dog	7 years [12]	Myc, BCL2 [21]	COP/CHOP	0.7 years

ISSN: 1479-5876